Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN

In English

Författare

  • Marie Fridberg
  • Anna Servin
  • Lola Anagnostaki
  • Johan Linderoth
  • Mattias Berglund
  • Ola Soderberg
  • Gunilla Enblad
  • Anders Rosen
  • Tomas Mustelin
  • Mats Jerkeman
  • Jenny L Persson
  • Anette Gjörloff Wingren
Visa allt

Summary, in English

Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) show varying responses to conventional therapy, and this might be contributed to the differentiation stage of the tumor B-cells. The aim of the current study was to evaluate a panel of kinases (ZAP70, PKC-beta I and II and phosphorylated PKB/Akt) and phosphatases (PTEN, SHP1 and SHP2) known to be frequently deregulated in lymphoid malignancies. De novo DLBCL cases were divided into two subgroups, the germinal center (GC) group (14/28) and the non-germinal center (non-GC) or activated B-cell (ABC) group (14/28). ZAP70 and PKC-beta II were expressed in a significantly higher percentage of tumor cells in the clinically more aggressive non-GC group compared with the prognostically favourable GC group. Also, the subcellular localization of PKC-beta I and II differed in DLBCL cells, with the PKC-beta I isoform being expressed in both the cytoplasm and nucleus, while PKC-beta II was found exclusively in the cytoplasm. Loss of nuclear PTEN correlated with poor survival in cases from both subgroups. In addition, five cell lines of DLBCL origin were analyzed for protein expression and for mRNA levels of PTEN and SHP1. For the first time, we show that ZAP70 is expressed in a higher percentage of tumor cells in the aggressive non-GC subgroup of DLBCL and that PKC-beta I and II are differently distributed in the two prognostic subgroups of de novo DLBCL.

Publiceringsår

2007

Språk

Engelska

Sidor

2221-2232

Publikation/Tidskrift/Serie

Leukemia & Lymphoma

Volym

48

Issue

11

Dokumenttyp

Artikel i tidskrift

Förlag

Taylor & Francis

Ämne

  • Cancer and Oncology

Nyckelord

  • B cell
  • lymphoma
  • germinal center
  • DLBCL
  • ZAP70
  • PKC-β

Status

Published

Forskningsgrupp

  • Pathology, Malmö

ISBN/ISSN/Övrigt

  • ISSN: 1042-8194